Vivalis grants rights to EB66 cell line for human vaccine to unnamed company

France-based biopharma company Vivalis (Euronext: VLS) says that it has signed a research agreement with an undisclosed worldwide vaccine company, granting the rights to evaluate the EB66 cell line for the production of a human vaccine candidate. Terms of the agreement were not disclosed

Franck Grimaud, chief executive, and Majid Mehtali, chief scientific officer, co-managers of Vivalis, stated: “This second agreement signed since the beginning of 2011 is a continuing demonstration that our EB66 cell platform is attracting an increasing number of vaccine companies. In conjunction with developed upstream and downstream industrial production processes along with an increasing body of regulatory approvals, the EB66 cell line strengthens its position as a global standard for the replacement of the traditional egg-based process for the production of viral vaccines for human and veterinary applications.”